Bernstein cuts Boston Scientific stock price target on device competition

Bernstein cut Boston Scientific’s price target to $54 from $60, maintaining an Outperform rating, as it warned Abbott’s Amulet 360 could raise its share of the left atrial appendage closure market from 10% to 20% in the near term and potentially approach a 50/50 split with Watchman. Boston Scientific shares were reported at $42.60, down 55% year to date and near a 52-week low of $41.94. Separately, Wells Fargo estimated the cyberattack’s eight days of downtime could reduce third-quarter sales by $300 million and EPS by $0.13; TD Cowen said distribution had recovered to at or above normal levels.

Analysis

BSX faces two different risks that should not be conflated: cyber-related disruption is principally a near-term execution and revenue-timing question, while Watchman competition could alter the longer-term growth and terminal-value case. If shipments normalize but Watchman adoption or procedure wins still weaken, the market may treat the problem as structural and compress the multiple; conversely, a clean operational recovery would remove one overhang without resolving the device threat. The key economic test is whether Amulet gains are incremental to the category or largely taken from Watchman, and whether portfolio bundling changes physician or hospital selection. ABT has a plausible strategic advantage if bundled offerings influence purchasing, but that does not establish durable share gains or improved consolidated earnings. BSX's electrophysiology strength is a counterweight, not proof that it offsets Watchman pressure. JNJ's potential response through acquisitions could intensify competition for assets and talent, but is too speculative to underwrite as a near-term catalyst. Over 1–3 months, watch BSX's quantified outage impact, recovery in shipments, and management commentary on Watchman procedure volumes. Over 6–18 months, adoption and share data matter more than analyst targets. The contrarian case is that the steep drawdown may already discount both a temporary disruption and an unproven competitive threat; without evidence of persistent share loss, an outright short has poor asymmetry.

Key Decisions for Investors

• Keep BSX exposure capped pending its full financial impact assessment. Track shipped orders, backlog conversion, and any guidance revision; treat the disruption as recoverable only if subsequent disclosures show normalization without persistent revenue or earnings impairment.
• Set an alert for a relative-value position—long ABT / short BSX—rather than initiating it solely on analyst commentary. Consider entry only after independent procedure or share data confirms sustained Amulet gains and BSX weakness; this thesis is falsified if Watchman holds share or BSX's electrophysiology growth offsets losses without margin deterioration.
• Avoid adding to BSX solely on apparent valuation cheapness. Reassess after the next earnings update against Watchman volumes, product-level growth, and the cyber impact; persistent share erosion or further downward guidance would argue for continued underweight, while stable adoption and clean shipment recovery would weaken the bearish case.
• Do not position for JNJ acquisition activity absent a named transaction or credible process evidence. Monitor deal announcements as a sector-wide competitive catalyst, but recognize that bidding pressure could raise acquisition costs rather than reliably benefit JNJ shareholders.